Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry

Authors: Danielle N. Blunt BMBS1,2, Liam Smyth MD, FRCPath1,3, Chenthila Nagamuthu MPH4, Evgenia Gatov MPH4, Ruth Croxford MSc4, Lee Mozessohn MD1, and Matthew C. Cheung MD, MSc1,4,5
View More View Less
  • 1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada;
  • | 2 Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia;
  • | 3 Department of Haematology, St. Vincent’s University Hospital, Dublin, Ireland; and
  • | 4 ICES, and
  • | 5 Division of Hematology/Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Restricted access

Background: Because of prolonged screening requirements, patient and time-dependent selection have been proposed as potential biases in clinical trials. The screening process may exclude patients with a need for emergent treatment (and a short period from diagnosis to treatment initiation [DTI]). We explored the impact of DTI on overall survival (OS) in a population-based cohort of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Using population-based administrative databases in Ontario, Canada, we identified adults aged ≥18 years with DLBCL treated with rituximab-based chemotherapy for curative intent between January 2005 and December 2015. Cox regression and multivariable analyses were presented to evaluate the impact of time from DTI on OS, controlling for relevant covariates. Results: We identified 9,441 patients with DLBCL in Ontario; median age was 66 years, 53.6% were male, median number of comorbidities (Johns Hopkins aggregated diagnosis groups) was 10 (interquartile range [IQR], 8–13), and median DTI was 37 days (IQR, 22–61). Between treatment initiation and study end, 43% of patients died (median OS, 1 year; IQR, 0.4–2.8 years). Shorter DTI was a significant predictor of mortality (P<.001). Compared with the shortest DTI period of 0–18 days, those who commenced therapy at 19–29 days (hazard ratio [HR], 0.75; 95% CI, 0.68–0.84), 30–41 days (HR, 0.70; 95% CI, 0.63–0.78), 42–57 days (HR, 0.52; 95% CI, 0.46–0.58), and 58–180 days (HR, 0.52; 95% CI, 0.47–0.58) had improved survival. Increasing age (HR, 1.03; 95% CI, 1.03–1.04), male sex (HR, 1.23; 95% CI, 1.14–1.32), and increasing number of comorbidities (HR, 1.12; 95% CI, 1.11–1.13) were associated with inferior survival. Conclusions: Among patients with DLBCL, shorter DTI was associated with inferior OS. Therefore, DTI may represent a surrogate marker for aggressive biology. Clinical trials with lengthy screening periods are likely creating a time-dependent patient selection bias.

Submitted June 18, 2020; final revision received September 13, 2020; accepted for publication September 15, 2020.

Published online March 10, 2021.

Previous presentation: Parts of this study were presented as a poster at the 60th American Society of Hematology Annual Meeting and Exposition; December 1–4, 2018; San Diego, California. Poster 4850.

Author contributions: Study concept and methodology: All authors. Data curation, formal analysis, resources and software and data validation: Nagamuthu, Gatov, Croxford. Project administration: Blunt, Smyth, Nagamuthu, Gatov. Study supervision: Croxford, Mozessohn, Cheung. Writing—original draft: Blunt, Smyth. Writing—review & editing: Nagamuthu, Gatov, Croxford, Mozessohn, Cheung.

Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Funding: This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI), Cancer Care Ontario (CCO), and Service Ontario.

Disclaimer: The analyses, conclusions, opinions, and statements expressed herein are those of the authors, and not necessarily those of CIHI, CCO, or Service Ontario; no endorsement is intended or should be inferred.

Correspondence: Danielle N. Blunt, BMBS, Department of Haematology, Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, Australia 5000. Email: danielle.blunt@sa.gov.au
  • 1.

    Rosenwald A, Wright G, Chan WC, et al. . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:19371947.

    • Search Google Scholar
    • Export Citation
  • 2.

    Davis RE, Brown KD, Siebenlist U, et al. . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:18611874.

    • Search Google Scholar
    • Export Citation
  • 3.

    Vitolo U, Witzig TE, Gascoyne RD, et al. . ROBUST: first report of phase III randomized study of lenalidomide/RCHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol 2019;37(Suppl 2):3637.

    • Search Google Scholar
    • Export Citation
  • 4.

    Younes A, Sehn LH, Johnson P, et al. . Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37:12851295.

    • Search Google Scholar
    • Export Citation
  • 5.

    Leonard JP, Kolibaba KS, Reeves JA, et al. . Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 2017;35:35383546.

    • Search Google Scholar
    • Export Citation
  • 6.

    Maurer MJ, Ghesquières H, Link BK, et al. . Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol 2018;36:16031610.

    • Search Google Scholar
    • Export Citation
  • 7.

    Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol 2018;181:495504.

    • Search Google Scholar
    • Export Citation
  • 8.

    Clarke EA, Marrett LD, Kreiger N. Cancer registration in Ontario: a computer approach. IARC Sci Publ 1991;95:246257.

  • 9.

    Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2010.

    • Search Google Scholar
    • Export Citation
  • 10.

    Hay K, Lee B, Goktepe O, et al. . Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2016;57:276282.

    • Search Google Scholar
    • Export Citation
  • 11.

    Camus V, Dubois S, Jardin F, et al. . Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study. Leuk Lymphoma 2019;60:839841.

    • Search Google Scholar
    • Export Citation
  • 12.

    Elliss-Brookes L, McPhail S, Ives A, et al. . Routes to diagnosis for cancer—determining the patient journey using multiple routine data sets. Br J Cancer 2012;107:12201226.

    • Search Google Scholar
    • Export Citation
  • 13.

    Kane E, Howell D, Smith A, et al. . Emergency admission and survival from aggressive non-Hodgkin lymphoma: a report from the UK’s population-based Haematological Malignancy Research Network. Eur J Cancer 2017;78:5360.

    • Search Google Scholar
    • Export Citation
  • 14.

    Nikonova A, Guirguis HR, Buckstein R, et al. . Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. Br J Haematol 2015;168:492500.

    • Search Google Scholar
    • Export Citation
  • 15.

    Ruan J, Martin P, Furman RR, et al. . Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690697.

    • Search Google Scholar
    • Export Citation
  • 16.

    Offner F, Samoilova O, Osmanov E, et al. . Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 2015;126:18931901.

    • Search Google Scholar
    • Export Citation
  • 17.

    Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. . Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:50585066.

    • Search Google Scholar
    • Export Citation
  • 18.

    Nowakowski GS, LaPlant B, Macon WR, et al. . Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 2015;33:251257.

    • Search Google Scholar
    • Export Citation
  • 19.

    Wilson WH, Young RM, Schmitz R, et al. . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922926.

    • Search Google Scholar
    • Export Citation
  • 20.

    Castellino A, Chiappella A, LaPlant BR, et al. . Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J 2018;8:108.

    • Search Google Scholar
    • Export Citation
  • 21.

    Nowakowski G, Chiappella A, Hong F, et al. . Potential factors that impact lenalidomide/R-CHOP efficacy in previously untreated diffuse large B-cell lymphoma in the ROBUST and ECOG-ACRIN 1412 studies [abstract]. Blood 2019;134(Suppl 1):4092. Abstract 626.

    • Search Google Scholar
    • Export Citation
  • 22.

    Tao L, Foran JM, Clarke CA, et al. . Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 2014;123:35533562.

    • Search Google Scholar
    • Export Citation
  • 23.

    Smith A, Crouch S, Howell D, et al. . Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol 2015;39:11031112.

    • Search Google Scholar
    • Export Citation
  • 24.

    Le Guyader-Peyrou S, Orazio S, Dejardin O, et al. . Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? Haematologica 2017;102:584592.

    • Search Google Scholar
    • Export Citation
  • 25.

    Boslooper K, Hoogendoorn M, van Roon EN, et al. . No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. Cancer Epidemiol 2017;48:110116.

    • Search Google Scholar
    • Export Citation
  • 26.

    Vetterlein MW, Löppenberg B, Karabon P, et al. . Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer 2017;123:32413252.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 730 730 730
PDF Downloads 384 384 384
EPUB Downloads 0 0 0